重组人BCMA蛋白 (Site-Specific PE Conjugation, ECD, His Tag)

Recombinant Human BCMA Protein (Site‑Specific PE Conjugation, ECD, His Tag)

Cat No: 10620‑H86H‑SP｜Official product page:        https://cn.sinobiological.com/recombinant-proteins/human-bcma-10620-h86h-sp

Specifications

Alternate Names

Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF‑receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF‑kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL‑1 and BCMA activates NF‑kappaB through a TRAF5‑, TRAF6‑, NIK‑, and IKK‑dependent pathway. The identification of TNFRSF17 as a NF‑kappaB‑activating receptor for TALL‑1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B‑cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell‑surface BCMA may contribute directly to tumor rejection in vivo.